BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported upbeat earnings for the first quarter on Wednesday.
The company posted quarterly earnings of 14 cents per share which beat the analyst consensus estimate of 5 cents per share. The company reported quarterly sales of $156.413 million which beat the analyst consensus estimate of $151.123 million.
BioCryst Pharma affirmed FY2026 sales guidance of $635.000 million-$660.000 million.
“We began 2026 with continued strong execution across our business, led by sustained growth of ORLADEYO and solid progress across our pipeline,” said Charlie Gayer, President and Chief Executive Officer of BioCryst. “ORLADEYO continues to grow because its differentiated oral profile and high level of attack control meet the needs of an increasing number of people living with hereditary …
This post was originally published here
